Axsome Therapeutics Inc’s recently made public that its Chief Operating Officer Jacobson Mark L. unloaded Company’s shares for reported $1.9 million on Apr 01 ’24. In the deal valued at $77.24 per share,24,662 shares were sold. As a result of this transaction, Jacobson Mark L. now holds 0 shares worth roughly $0.0.
Then, JEFFS ROGER sold 2,347 shares, generating $168,062 in total proceeds. Upon selling the shares at $71.61, the Director now owns 120,756 shares.
Before that, JEFFS ROGER sold 29,976 shares. Axsome Therapeutics Inc shares valued at $2,089,387 were divested by the Director at a price of $69.70 per share. As a result of the transaction, JEFFS ROGER now holds 120,756 shares, worth roughly $9.17 million.
Morgan Stanley upgraded its Axsome Therapeutics Inc [AXSM] rating to an Overweight from a an Equal-weight in a research note published on April 29, 2024; the price target was increased to $115 from $90. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. UBS began covering AXSM with “Buy” recommendation on February 06, 2024. RBC Capital Mkts started covering the stock on January 25, 2024. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Monday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock jump 1.52% to $75.94. Over the last five days, the stock has gained 3.05%. Axsome Therapeutics Inc shares have fallen nearly -4.59% since the year began. Nevertheless, the stocks have risen 6.73% over the past one year. While a 52-week high of $98.40 was reached on 02/12/24, a 52-week low of $55.02 was recorded on 04/19/24. SMA at 50 days reached $74.33, while 200 days put it at $74.80. A total of 0.94 million shares were traded, compared to the trading of 0.4 million shares in the previous session.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 73.51, which if violated will result in even more drops to 71.07. On the upside, there is a resistance level at 78.18. A further resistance level may holdings at 80.41. The Relative Strength Index (RSI) on the 14-day chart is 57.28, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.89, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 16.35%. Stochastics %K at 82.95% indicates the stock is a selling.
The most recent change occurred on December 13, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $125 price target.
